{name}
{subtitle}
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~7 mi. (Burlington, Vermont, +192 more cities)
facility
University of Vermont Medical Center
biomarker
ER Positive, +1 more biomarker
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
city
~7 mi. (Burlington, Vermont, +226 more cities)
facility
University of Vermont Medical Center
biomarker
EGFR Exon 19 Deletion, +1 more biomarker
drug
amivantamab, +3 more drugs
drug type
chemotherapy, +1 more type
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
city
~7 mi. (Burlington, Vermont, +523 more cities)
facility
University of Vermont Medical Center
drug
cabozantinib, +2 more drugs
drug type
immunotherapy, +1 more type
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
city
~7 mi. (Burlington, Vermont, +744 more cities)
facility
University of Vermont and State Agricultural College, +1 more facility
drug type
radiation therapy, +1 more type
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
city
~7 mi. (Burlington, Vermont, +454 more cities)
facility
University of Vermont and State Agricultural College
drug
brentuximab vedotin, +7 more drugs
drug type
chemotherapy, +3 more types
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~7 mi. (Burlington, Vermont, +130 more cities)
facility
University of Vermont Medical Center ( Site 1057)
drug
BCG solution, +1 more drug
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
city
~7 mi. (Burlington, Vermont, +174 more cities)
facility
University of Vermont Cancer Center
drug
chemoradiotherapy, +3 more drugs
drug type
chemotherapy, +2 more types
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
city
~7 mi. (Burlington, Vermont, +825 more cities)
facility
University of Vermont Medical Center, +1 more facility
biomarker
AKT1 Mutation, +91 more biomarkers
condition
Breast Carcinoma, +3 more conditions
drug
adavosertib, +26 more drugs
drug type
immunotherapy, +1 more type